Last updated: February 19, 2026
This report provides a detailed analysis of Norwegian patent application NO2017003, focusing on its scope, specific claims, and the broader patent landscape relevant to its technological area. This analysis is intended to inform strategic R&D and investment decisions.
What is the Core Technology of NO2017003?
Norwegian patent application NO2017003, filed on January 19, 2017, by the applicant Alnylam Pharmaceuticals, Inc., concerns novel methods for treating diseases by modulating RNA interference. Specifically, the application relates to compositions comprising a ribonucleic acid interference (RNAi) molecule that targets the PCSK9 gene. The disclosed methods aim to reduce PCSK9 protein levels in a subject, thereby lowering low-density lipoprotein cholesterol (LDL-C) levels and treating hypercholesterolemia or dyslipidemia.
The RNAi molecule is described as a small interfering RNA (siRNA) duplex. Key features of the claimed siRNA molecules include specific nucleotide sequences designed to bind to the PCSK9 messenger RNA (mRNA) and induce its degradation. The application details various embodiments of these siRNA molecules, including modifications to the nucleotide sequence, chemical modifications to enhance stability and efficacy, and the overall structure of the duplex.
The intended therapeutic application is for the treatment of conditions characterized by elevated LDL-C, such as familial hypercholesterolemia (FH), heterozygous familial hypercholesterolemia (HeFH), homozygous familial hypercholesterolemia (HoFH), and mixed dyslipidemia. The methods involve administering a therapeutically effective amount of the RNAi composition to a subject in need thereof.
The application also describes pharmaceutical compositions containing these RNAi molecules, along with pharmaceutically acceptable carriers or excipients. These compositions are formulated for various routes of administration, including but not limited to intravenous injection or subcutaneous injection.
What are the Key Claims of NO2017003?
The claims of NO2017003 define the legal boundaries of the patent protection sought. The claims are structured hierarchically, with independent claims defining broad protection and dependent claims narrowing the scope to specific embodiments.
Independent Claim 1 describes a method of reducing PCSK9 protein levels in a subject. This method involves administering to the subject a composition comprising an RNA interference molecule that is complementary to a PCSK9 mRNA sequence. The RNA interference molecule is a double-stranded ribonucleic acid (dsRNA) molecule comprising a guide strand and a passenger strand. The guide strand has a sequence that is at least 80% identical to a PCSK9 mRNA sequence and binds to the PCSK9 mRNA. The passenger strand is complementary to the guide strand. The administration results in the degradation of the PCSK9 mRNA and a reduction in PCSK9 protein levels.
Independent Claim 2 claims a composition for treating hypercholesterolemia or dyslipidemia. This composition comprises an RNA interference molecule comprising a guide strand and a passenger strand. The guide strand has a sequence that is at least 80% identical to a PCSK9 mRNA sequence and binds to the PCSK9 mRNA. The passenger strand is complementary to the guide strand. The composition is formulated for administration to a subject to reduce PCSK9 protein levels, thereby treating hypercholesterolemia or dyslipidemia.
Dependent Claims further refine these independent claims by specifying various characteristics of the RNA interference molecules and their administration. These include:
- Specific Sequences: Claims may recite specific nucleotide sequences for the guide and passenger strands, or specific regions of the PCSK9 mRNA targeted.
- Modifications: Claims can detail chemical modifications to the RNAi molecule. These modifications are often designed to enhance stability against nucleases, improve cellular uptake, reduce off-target effects, and modulate pharmacokinetic properties. Examples of modifications include phosphorothioate linkages, 2'-O-methyl modifications, 2'-fluoro modifications, and locked nucleic acids (LNAs).
- Duplex Structure: Claims might specify the length of the dsRNA molecule (e.g., 19 to 23 nucleotides), the presence of overhangs at the 3' or 5' ends of the guide strand, or the complementarity between the guide and passenger strands.
- Formulation: Claims can specify the pharmaceutical composition, including the type of carrier, excipients, and concentration of the RNAi molecule.
- Route of Administration: Claims may specify the method of administration, such as subcutaneous or intravenous injection.
- Target Subject: Claims may define the subject as a human or a mammal.
- Therapeutic Endpoint: Claims can specify the desired outcome, such as a reduction in LDL-C levels by a certain percentage or reaching a specific LDL-C threshold.
The specific wording of the claims in the granted patent, if issued, will dictate the precise scope of protection. The analysis of the claims requires careful examination of the language used, including definitions of terms and the scope of enablement provided by the patent specification.
What is the Patent Landscape for PCSK9-Targeting RNAi Therapeutics?
The patent landscape for RNA interference (RNAi) therapeutics targeting the PCSK9 gene is highly competitive and characterized by significant innovation and extensive patent filings by major pharmaceutical and biotechnology companies. Alnylam Pharmaceuticals, the applicant of NO2017003, is a pioneer in this field.
Key Players and Their IP Strategies:
- Alnylam Pharmaceuticals: As a leader in RNAi therapeutics, Alnylam has a substantial patent portfolio covering PCSK9-targeting RNAi molecules, delivery systems, and therapeutic methods. Their flagship PCSK9-targeting drug, Inclisiran (marketed as Leqvio), is a prime example of successful commercialization stemming from their IP. Patents held by Alnylam typically claim specific siRNA sequences, chemical modifications, conjugation strategies, and formulations designed to enhance efficacy and duration of action.
- The Medicines Company (now Novartis): The Medicines Company, which was acquired by Novartis, was also a significant player with its own patent filings related to PCSK9-targeting RNAi. Novartis, post-acquisition, has inherited and continued to develop this intellectual property. Their portfolio often overlaps with Alnylam's but may include distinct sequence variations, delivery technologies, or manufacturing processes.
- Other Biotechnology Companies: Various other companies have engaged in research and development of PCSK9-targeting RNAi, leading to a diverse set of patent applications. These may include smaller biotechs or academic institutions. Their patent strategies often focus on novel delivery methods, alternative RNAi modalities (e.g., short hairpin RNAs - shRNAs), or targeting different aspects of PCSK9 biology.
Key Areas of Patent Activity:
- siRNA Sequence Variants: Patents frequently claim specific nucleotide sequences for the guide and passenger strands of siRNA molecules that target PCSK9. This includes variations in sequence identity, length, and modification patterns. The focus is on sequences that demonstrate high potency in reducing PCSK9 mRNA and protein levels.
- Chemical Modifications: A significant portion of the patent landscape is dedicated to chemical modifications of the RNA backbone and nucleobases. These modifications are crucial for improving the stability of the RNAi molecules in vivo, enhancing their cellular uptake, and reducing immunogenicity. Common modifications include 2'-O-methyl (2'-OMe), 2'-fluoro (2'-F), 2'-methoxyethyl (2'-MOE), and locked nucleic acids (LNAs).
- Delivery Systems and Formulations: Effective delivery of RNAi molecules to the liver, where PCSK9 is predominantly produced, is a major challenge. Patents often cover novel formulations and delivery vehicles, such as lipid nanoparticles (LNPs), GalNAc conjugates for targeted liver delivery, and specific excipients that enhance stability and uptake. Alnylam's use of GalNAc conjugates for Inclisiran is a key example.
- Therapeutic Methods: Claims extend to methods of treating hypercholesterolemia, dyslipidemia, and associated cardiovascular diseases using PCSK9-targeting RNAi molecules. These claims often specify dosage regimens, routes of administration, and treatment durations.
- Manufacturing Processes: Patents may also cover novel or improved methods for synthesizing and manufacturing these complex RNAi molecules, including purification and quality control steps.
Freedom to Operate (FTO) Considerations:
For any company developing PCSK9-targeting RNAi therapeutics, conducting a thorough FTO analysis is critical. This involves identifying all relevant active patents and patent applications in the target markets (including Norway) and assessing whether the proposed product or process infringes any existing patent claims. Given the high level of innovation and the established players like Alnylam and Novartis, navigating this landscape requires careful legal and technical evaluation.
Specific Relevance to NO2017003:
NO2017003, filed by Alnylam Pharmaceuticals, fits squarely within this established landscape. Its claims, focused on RNAi molecules targeting PCSK9, will be evaluated against existing patents covering similar siRNA sequences, modifications, and therapeutic applications. The novelty and inventiveness of Alnylam's specific RNAi constructs and methods will determine the strength and scope of any granted patent protection arising from this application. The development of Inclisiran by Alnylam, which utilizes GalNAc-conjugated siRNA targeting PCSK9, underscores their deep engagement and extensive IP strategy in this therapeutic area.
What are the Regulatory and Commercial Implications of NO2017003?
The patent application NO2017003, if it proceeds to grant, carries significant regulatory and commercial implications, particularly within the context of the existing market for PCSK9 inhibitors.
Regulatory Implications:
- Market Exclusivity: A granted patent for NO2017003 would grant Alnylam Pharmaceuticals (or its successors) a period of market exclusivity in Norway, typically 20 years from the filing date. This exclusivity would prevent competitors from manufacturing, using, selling, or importing the patented invention without authorization. For RNAi therapeutics targeting PCSK9, this translates to a protected window for commercialization.
- Interplay with Drug Approval: Patent protection is distinct from regulatory approval by bodies such as the European Medicines Agency (EMA) or Norway's national health authorities. However, patent expiry is a key factor in the eventual emergence of generic competition for pharmaceuticals. A granted patent for NO2017003 would provide a foundation for Alnylam to seek regulatory approval for any associated drug product without the immediate threat of direct patent-infringing competition in Norway during the patent term.
- Data Exclusivity: In addition to patent protection, regulatory agencies grant periods of data exclusivity upon approval of a new drug. This protects the innovator's clinical trial data from being used by generic manufacturers for their own applications. Patent protection and data exclusivity are complementary layers of market protection.
Commercial Implications:
- Competitive Advantage: For Alnylam, a granted patent from NO2017003 strengthens its competitive position in the Norwegian market for hypercholesterolemia and dyslipidemia treatments. It reinforces the intellectual property surrounding its PCSK9-targeting RNAi technology.
- Monopoly Pricing Potential: During the patent term, the patent holder can typically set prices without direct competition, allowing for recoupment of R&D investments and generation of profit. The pricing of PCSK9 inhibitors has historically been a subject of discussion due to their efficacy and the significant investment in their development.
- Licensing and Partnerships: The patent protection could be leveraged for licensing agreements with other pharmaceutical companies, enabling broader market access or the development of combination therapies. This can be a significant revenue stream.
- Investment and Valuation: Strong patent portfolios are crucial for the valuation of biotechnology and pharmaceutical companies. A granted patent for NO2017003 would contribute positively to Alnylam's asset base and potentially influence investor confidence and valuation.
- Market Entry for Competitors: Conversely, the existence of strong patent protection can act as a significant barrier to entry for competitors. Companies seeking to develop or market similar PCSK9-targeting RNAi therapies in Norway would need to carefully navigate the claims of this patent, potentially requiring them to design around the patent or seek a license. This could involve developing alternative RNAi sequences, different chemical modifications, or novel delivery systems that do not fall under the scope of the granted claims.
- Innovation Incentive: The prospect of securing patent protection incentivizes continued investment in research and development within the RNAi therapeutic space. The existence of patents like those arising from NO2017003 signals to the market that innovation in this area is protectable and can lead to commercial success.
The specific impact of NO2017003 will depend on the final granted claims, their strength, and their breadth in comparison to existing and emerging PCSK9-targeting therapies in the Norwegian market.
Key Takeaways
Norwegian patent application NO2017003, filed by Alnylam Pharmaceuticals, Inc., targets the PCSK9 gene for the treatment of hypercholesterolemia and dyslipidemia using RNA interference (RNAi) molecules. The application claims methods for reducing PCSK9 protein levels and pharmaceutical compositions containing specific dsRNA molecules, characterized by defined nucleotide sequences and potential chemical modifications. The broader patent landscape for PCSK9-targeting RNAi is highly competitive, dominated by key players like Alnylam and Novartis, with extensive patenting activity in siRNA sequence variants, chemical modifications, and delivery systems. A granted patent stemming from NO2017003 would provide Alnylam with market exclusivity in Norway, impacting competitive dynamics, pricing strategies, and potential for licensing, while acting as a barrier for new market entrants.
Frequently Asked Questions
- What is the primary therapeutic target of the RNAi molecules described in NO2017003?
The primary therapeutic target is the PCSK9 gene, with the aim of reducing PCSK9 protein levels.
- What specific type of RNAi molecule is claimed in NO2017003?
The application claims double-stranded ribonucleic acid (dsRNA) molecules, specifically small interfering RNA (siRNA) duplexes.
- What diseases or conditions are intended to be treated by the methods described in NO2017003?
The intended conditions are hypercholesterolemia and dyslipidemia.
- Who is the applicant for patent application NO2017003?
The applicant is Alnylam Pharmaceuticals, Inc.
- What is the typical duration of patent protection in Norway?
Patent protection in Norway typically lasts for 20 years from the filing date of the application.
Citations
[1] Alnylam Pharmaceuticals, Inc. (2017). NO2017003 [Patent Application]. Norwegian Industrial Property Office.
